ResMed
Q4 2022 Earnings Call
Aug 11, 2022, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Hello, and welcome to the Q4 Fiscal Year 2022 ResMed earnings conference call. My name is Kevin, and I'll be your operator for today's call. [Operator instructions] Please note that this conference is being recorded. I will now turn the call over to Amy Wakeham, vice president of investor relations and corporate communications.
Amy, you may begin.
Amy Wakeham -- Vice President of Investor Relations and Corporate Communications
Great. Thank you, Kevin, and hi, everyone. Welcome to ResMed's fourth quarter fiscal year 2022 earnings conference call. We thank you for joining us.
This call is being webcast live, and the replay will be available on the investor relations section of our corporate website later today, along with a copy of our earnings release and the presentation, both of which are available now. Joining me on the call today are our chief executive officer, Mick Farrell, and chief financial officer, Brett Sandercock. Following our prepared remarks, we will host a Q&A session, and Mick and Brett will be joined by Rob Douglas, president and chief operating officer, and David Pendarvis, chief administrative officer and global general counsel. During today's call, we will discuss several non-GAAP measures.
For a reconciliation of the non-GAAP measures, please review the supporting schedules in today's earnings press release. And as a reminder, our discussion today will include forward-looking statements, including, but not limited to, expectations about our future operating and financial performance. We believe these statements are based on reasonable assumptions. However, our actual results may differ.
Please refer to our SEC filings for a complete discussion of the risk factors that could cause our actual results to differ materially from any forward-looking statements made today. I'll now go ahead and turn the call over to Mick.
Mick Farrell -- Chief Executive Officer
Thanks, Amy, and thank you all for joining us today as we review the results for the fourth quarter of our fiscal year 2022 ended June 30. On today's call, I will provide a brief high-level overview of our financial results. I'll then review progress toward our ResMed 2025 strategic goals, and then discuss our actions to navigate through ongoing industry and supply chain challenges. Brett will then join the call to review our financial results in more detail.